- Home
- /
- Drugs
- /
- L
- /
- LENALIDOMIDE
- /
- LENALIDOMIDE LENALIDOMIDE 2.5 mg/1 Zydus Lifesciences Limited
LENALIDOMIDE
- Lenalidomide LENALIDOMIDE 2.5 mg/1 Aurobindo Pharma Limited
- Lenalidomide LENALIDOMIDE 2.5 mg/1 Dr. Reddy's Laboratories Inc.
- Revlimid LENALIDOMIDE 2.5 mg/1 Celgene Corporation
- LENALIDOMIDE LENALIDOMIDE 2.5 mg/1 Zydus Pharmaceuticals USA Inc.
- Lenalidomide LENALIDOMIDE 2.5 mg/1 Sun Pharmaceutical Industries, Inc.
- LENALIDOMIDE LENALIDOMIDE 2.5 mg/1 Alvogen, Inc.
- Lenalidomide LENALIDOMIDE 2.5 mg/1 Mylan Pharmaceuticals Inc.
- Lenalidomide LENALIDOMIDE 2.5 mg/1 Apotex Corp.
- Lenalidomide LENALIDOMIDE 2.5 mg/1 Aurobindo Pharma Limited
- Lenalidomide LENALIDOMIDE 2.5 mg/1 Teva Pharmaceuticals, Inc.
- LENALIDOMIDE LENALIDOMIDE 2.5 mg/1 Camber Pharmaceuticals, Inc.
- LENALIDOMIDE LENALIDOMIDE 2.5 mg/1 Zydus Lifesciences Limited
- Lenalidomide LENALIDOMIDE 2.5 mg/1 Apotex Corp.
- Lenalidomide LENALIDOMIDE 2.5 mg/1 Cipla USA Inc.
- Lenalidomide LENALIDOMIDE 2.5 mg/1 Mylan Pharmaceuticals Inc.
- LENALIDOMIDE LENALIDOMIDE 2.5 mg/1 Zydus Pharmaceuticals USA Inc.
- LENALIDOMIDE LENALIDOMIDE 2.5 mg/1 Zydus Lifesciences Limited
Summary of product characteristics
Effective Time
20230927
Version
3
Spl Product Data Elements
LENALIDOMIDE LENALIDOMIDE LENALIDOMIDE LENALIDOMIDE ANHYDROUS LACTOSE CELLULOSE, MICROCRYSTALLINE CROSCARMELLOSE SODIUM FERROSOFERRIC OXIDE GELATIN LACTOSE MONOHYDRATE MAGNESIUM STEARATE POTASSIUM HYDROXIDE SHELLAC TITANIUM DIOXIDE white opaque cap with white opaque body capsule 1031 LENALIDOMIDE LENALIDOMIDE LENALIDOMIDE LENALIDOMIDE ANHYDROUS LACTOSE CELLULOSE, MICROCRYSTALLINE CROSCARMELLOSE SODIUM D&C RED NO. 33 D&C YELLOW NO. 10 FD&C BLUE NO. 1 FERROSOFERRIC OXIDE GELATIN LACTOSE MONOHYDRATE MAGNESIUM STEARATE POTASSIUM HYDROXIDE SHELLAC TITANIUM DIOXIDE White opaque cap Turquoise blue opaque body capsule 1032 LENALIDOMIDE LENALIDOMIDE LENALIDOMIDE LENALIDOMIDE ANHYDROUS LACTOSE CELLULOSE, MICROCRYSTALLINE CROSCARMELLOSE SODIUM D&C RED NO. 28 FD&C BLUE NO. 1 FERROSOFERRIC OXIDE GELATIN LACTOSE MONOHYDRATE MAGNESIUM STEARATE POTASSIUM HYDROXIDE SHELLAC TITANIUM DIOXIDE White opaque cap Light Blue opaque body capsule 1033 LENALIDOMIDE LENALIDOMIDE LENALIDOMIDE LENALIDOMIDE ANHYDROUS LACTOSE CELLULOSE, MICROCRYSTALLINE CROSCARMELLOSE SODIUM D&C RED NO. 28 FD&C BLUE NO. 1 FERROSOFERRIC OXIDE GELATIN LACTOSE MONOHYDRATE MAGNESIUM STEARATE POTASSIUM HYDROXIDE SHELLAC TITANIUM DIOXIDE White opaque cap Light Blue opaque body capsule 1035 LENALIDOMIDE LENALIDOMIDE LENALIDOMIDE LENALIDOMIDE ANHYDROUS LACTOSE CELLULOSE, MICROCRYSTALLINE CROSCARMELLOSE SODIUM FD&C BLUE NO. 1 FD&C RED NO. 40 FD&C YELLOW NO. 6 FERROSOFERRIC OXIDE GELATIN LACTOSE MONOHYDRATE MAGNESIUM STEARATE POTASSIUM HYDROXIDE SHELLAC TITANIUM DIOXIDE white opaque cap with blue opaque body capsule 1030 LENALIDOMIDE LENALIDOMIDE LENALIDOMIDE LENALIDOMIDE ANHYDROUS LACTOSE CELLULOSE, MICROCRYSTALLINE CROSCARMELLOSE SODIUM D&C RED NO. 28 D&C RED NO. 33 D&C YELLOW NO. 10 FD&C BLUE NO. 1 FERROSOFERRIC OXIDE GELATIN LACTOSE MONOHYDRATE MAGNESIUM STEARATE POTASSIUM HYDROXIDE SHELLAC TITANIUM DIOXIDE light blue opaque cap turquoise blue opaque body capsule 1034
Application Number
ANDA210154
Brand Name
LENALIDOMIDE
Generic Name
LENALIDOMIDE
Product Ndc
70771-1676
Product Type
HUMAN PRESCRIPTION DRUG
Route
ORAL
Package Label Principal Display Panel
PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 70771-1676-7 Lenalidomide Capsules, 2.5 mg 28 Capsules Rx only NDC 70771-1677-7 Lenalidomide Capsules, 5 mg 28 Capsules Rx only NDC 70771-1678-7 Lenalidomide Capsules, 10 mg 28 Capsules Rx only NDC 70771-1679-8 Lenalidomide Capsules, 15 mg 21 Capsules Rx only NDC 70771-1680-8 Lenalidomide Capsules, 20 mg 21 Capsules Rx only NDC 70771-1681-8 Lenalidomide Capsules, 25 mg 21 Capsules Rx only 2.5 mg label 5 mg label 10 mg label 15 mg label 20 mg label 25 mg label
Spl Medguide
SPL MEDGUIDE
Drug section
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
Disclaimer
The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).
Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.
Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.